LONG-TERM DUAL ANTIPLATELET THERAPY: CONTROVERSY CONTINUES

E Martínez Ruiz1, P Tardáguila Molina1, I Corredor Martiarena2, G Casarrubios Lázaro1, I Mendoza Acosta1. Pharmacy Department1, Hospital Emergency Department2. Guadalajara University Hospital, Guadalajara, Spain

BACKGROUND AND IMPORTANCE

Long-term dual antiplatelet therapy (DAPT) is one of the most researched therapies that involves the combination of acetylsalicylic acid (ASA) and platelet adenosine diphosphate receptor inhibitor (P2Y12). The main indication for DAPT is prevention of coronary events after an acute coronary syndrome (ACS) or after a percutaneous coronary intervention (PCI) but in practice, there is a confusion around. Recommendations indicate that DAPT can be maintained over a year depending on the ischemic and hemorrhagic risk of each patient.

AIM AND OBJECTIVES

The aim of this study was investigate DAPT indications and risk factors related to extending this therapy for over a year despite the fact that suspension of one antiplatelet drug was indicated (medication discrepancies).

MATERIAL AND METHODS

Of a total number of 221 patients with DAPT from January 2009-2020, this observational and retrospective study was based on a simple random sampling including 33% of the total of patients. ✓ Data were obtained by review of electronic medical records. ✓ Variables collected: demographic, clinical services, DAPT indication, drugs used, durability, risk factors of extending DAPT and medication discrepancies.

RESULTS

✓ 91.4% of patients had indication for use DAPT.
✓ 8.6% of patients had no indication for DAPT.
✓ 8.6% of patients had medication discrepancies.

CONCLUSION AND RELEVANCE

✓ Many patients had indication for DAPT at the beginning of treatment and had risk factors that justify long-term DAPT but duration was not evaluated.
✓ It is necessary a multidisciplinary team to manage this therapy, considering risk-benefit of each patient.

ATC code: 4. Historical research